These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2967352)

  • 1. Brain quinolinic acid in Huntington's disease.
    Reynolds GP; Pearson SJ; Halket J; Sandler M
    J Neurochem; 1988 Jun; 50(6):1959-60. PubMed ID: 2967352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain quinolinic acid in Alzheimer's dementia.
    Sofic E; Halket J; Przyborowska A; Riederer P; Beckmann H; Sandler M; Jellinger K
    Eur Arch Psychiatry Neurol Sci; 1989; 239(3):177-9. PubMed ID: 2532134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quinolinic acid hypothesis in Huntington's chorea.
    Bruyn RP; Stoof JC
    J Neurol Sci; 1990 Jan; 95(1):29-38. PubMed ID: 2159984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.
    Ellison DW; Beal MF; Mazurek MF; Malloy JR; Bird ED; Martin JB
    Brain; 1987 Dec; 110 ( Pt 6)():1657-73. PubMed ID: 2892568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease.
    Heyes MP; Swartz KJ; Markey SP; Beal MF
    Neurosci Lett; 1991 Jan; 122(2):265-9. PubMed ID: 1827518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
    Beal MF; Kowall NW; Ellison DW; Mazurek MF; Swartz KJ; Martin JB
    Nature; 1986 May 8-14; 321(6066):168-71. PubMed ID: 2422561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal excretion of quinolinic acid in Huntington's disease.
    Heyes MP; Garnett ES; Brown RR
    Life Sci; 1985 Nov; 37(19):1811-6. PubMed ID: 2932618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of quinolinic acid in rat brain, whole blood, and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic L-tryptophan administration on brain and blood quinolinic acid concentrations.
    Heyes MP; Markey SP
    Anal Biochem; 1988 Oct; 174(1):349-59. PubMed ID: 2975477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia.
    Schwarcz R; Tamminga CA; Kurlan R; Shoulson I
    Ann Neurol; 1988 Oct; 24(4):580-2. PubMed ID: 2977086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolinic acid concentrations in striatal extracellular fluid reach potentially neurotoxic levels following systemic L-tryptophan loading.
    During MJ; Heyes MP; Freese A; Markey SP; Martin JB; Roth RH
    Brain Res; 1989 Jan; 476(2):384-7. PubMed ID: 2522807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease.
    Alam ZI; Halliwell B; Jenner P
    J Neurochem; 2000 Aug; 75(2):840-6. PubMed ID: 10899962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala
    Verma MK; Goel R; Nandakumar K; Nemmani KVS
    Eur J Pharmacol; 2018 Jun; 828():31-41. PubMed ID: 29577894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil.
    Heyes MP; Nowak TS
    J Cereb Blood Flow Metab; 1990 Sep; 10(5):660-7. PubMed ID: 1696582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral cation shifts and amino acids in Huntington's disease.
    Gramsbergen JB; Veenma-Van der Duin L; Venema K; Korf J
    Arch Neurol; 1986 Dec; 43(12):1276-81. PubMed ID: 2877650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease.
    Cross AJ; Slater P; Reynolds GP
    Neurosci Lett; 1986 Jun; 67(2):198-202. PubMed ID: 2873534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
    Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
    Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during the aging process.
    Moroni F; Lombardi G; Moneti G; Aldinio C
    Neurosci Lett; 1984 Jun; 47(1):51-5. PubMed ID: 6235466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of quinolinic acid into rabbit and rat brain.
    Kitt TM; Spector R
    Neurochem Res; 1987 Jul; 12(7):625-8. PubMed ID: 2956529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid.
    Davies SW; Roberts PJ
    Nature; 1987 May 28-Jun 3; 327(6120):326-9. PubMed ID: 2884569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine.
    Moroni F; Russi P; Gallo-Mezo MA; Moneti G; Pellicciari R
    J Neurochem; 1991 Nov; 57(5):1630-5. PubMed ID: 1833509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.